Year To Quarter End Consolidated Statement Of Income

Oncolys BioPharma Inc. - Filing #7342826

Concept 2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
Year to quarter end consolidated statement of income
Statement of income
Net sales
63,038,000 JPY
976,182,000 JPY
Gross profit (loss)
30,604,000 JPY
338,487,000 JPY
Selling, general and administrative expenses
Remuneration for directors (and other officers)
101,308,000 JPY
90,778,000 JPY
Taxes and dues
25,552,000 JPY
20,862,000 JPY
Selling, general and administrative expenses
1,960,591,000 JPY
1,542,993,000 JPY
Operating profit (loss)
-1,929,986,000 JPY
-1,204,506,000 JPY
Non-operating income
Interest income
1,475,000 JPY
587,000 JPY
Dividend income
3,000 JPY
3,000 JPY
Non-operating income
32,208,000 JPY
63,267,000 JPY
Non-operating expenses
Interest expenses
3,602,000 JPY
3,945,000 JPY
Non-operating expenses
16,038,000 JPY
21,769,000 JPY
Ordinary profit (loss)
-1,913,816,000 JPY
-1,163,008,000 JPY
Extraordinary income
Gain on sale of non-current assets
136,000 JPY
JPY
Extraordinary income
136,000 JPY
21,406,000 JPY
Extraordinary losses
Impairment losses
21,898,000 JPY
4,403,000 JPY
Extraordinary losses
21,898,000 JPY
4,403,000 JPY
Profit (loss) before income taxes
-1,935,578,000 JPY
-1,146,005,000 JPY
Income taxes - current
2,926,000 JPY
2,932,000 JPY
Income taxes
2,926,000 JPY
2,932,000 JPY
Profit (loss)
-1,938,505,000 JPY
-1,938,505,000 JPY
-1,938,505,000 JPY
-1,938,505,000 JPY
-1,148,938,000 JPY
-1,148,938,000 JPY
-1,148,938,000 JPY
-1,148,938,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.